January to September 2025:
HARTMANN increases sales despite weaker markets

Heidenheim, 20 November 2025. The HARTMANN GROUP held its own in a challenging market environment in the period from January to September 2025, achieving organic sales growth of 2.0%. Sales revenues amounted to EUR 1,826.0 million.

HARTMANN gained market share in strategic core segments. However, sales markets weakened in some regions, particularly in the area of prescription wound care products in Germany and France.

Adjusted EBITDA amounted to EUR 195.8 million after nine months, down EUR 18.2 million on the previous year. The adjusted EBITDA margin was 10.7%. This development was primarily attributable to weaker sales markets, sales and marketing expenses for the launch of new products incurred earlier than planned, and higher material costs.

The structured employee survey conducted in the third quarter with the Gallup research institute revealed a further increase in the commitment of HARTMANN GROUP employees worldwide.

Sales in the Incontinence Management segment increased again, primarily due to the strategically important area of incontinence pants, but also due to products for light incontinence, as well as skin and patient care.

In the Wound Care segment, sales growth was based in particular on developments in the strategic growth areas of atraumatic dressings, such as Zetuvit® Plus Silicone and Resposorb® Silicone.

Sales in the Infection Management segment were also higher than in the same period of the previous year. While sales of surface and hand disinfection products as well as MediSets® and CombiSets® increased, the retail business with protective products declined.

Sales in the Complementary Group Divisions segment declined slightly.

HARTMANN is pursuing a cautious cost management strategy due to many uncertainties in the markets. At the same time, the Company is consistently investing in innovation projects and growth. Despite ongoing market pressures, as well as trade and geopolitical uncertainties, HARTMANN continues to expect moderate organic sales growth and confirms its forecast for adjusted EBITDA of EUR 250 to 290 million.

Further information on HARTMANN’s financial situation can be found at https://corporate.hartmann.info/de-de/investor-relations.

The HARTMANN GROUP is one of the leading European providers of professional medical and care products and associated services. Every day, healthcare professionals and patients rely on HARTMANN brands in the segments of Incontinence Management (e.g. MoliCare®), Wound Care (e.g. Zetuvit®, Cosmopor®) and Infection Management (e.g. Sterillium®). This is expressed in our brand promise of “Helps. Cares. Protects.” Founded in 1818, the Company sells its products and solutions in 130 countries around the world.

To learn more about the HARTMANN GROUP, visit www.corporate.hartmann.info.